Global Biologics Testing Market Size and Forecast 2024-2033|harles River Laboratories Inc., Thermo Fisher Scientific Inc., Merck KGaA, SGS Société Générale de Surveillance SA, WuXi AppTec Co. Ltd

Scientific analysis of wastewater sample in laboratory, investigation of possible contamination by Sars-Cov-2 in humans, conceptual image

The Biologics Testing Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Biologics Testing Market:

https://www.thebusinessresearchcompany.com/report/biologics-testing-global-market-report

According to The Business Research Company’s Biologics Testing Global Market Report 2024, The biologics testing market size has grown rapidly in recent years. It will grow from $5.09 billion in 2023 to $5.88 billion in 2024 at a compound annual growth rate (CAGR) of 15.6%. The growth in the historic period can be attributed to growth in biologics development, stringent regulatory standards, quality control in bioprocessing, rise in biopharmaceutical investments, expansion of biomanufacturing capacity.

The biologics testing market size is expected to see rapid growth in the next few years. It will grow to $10.82 billion in 2028 at a compound annual growth rate (CAGR) of 16.5%. The growth in the forecast period can be attributed to emergence of advanced therapies, increasing demand for contract testing services, expansion of biologics pipelines, globalization of biopharmaceutical manufacturing, increasing demand for rapid testing solutions. Major trends in the forecast period include advanced analytical technologies, cell-based assays, next-generation sequencing (ngs), quality by design (qbd) principles, integration of artificial intelligence (ai), rapid methods for product release.

The rapidly growing pharmaceutical and biotechnology industries are expected to propel the growth of the biologics testing market going forward. The pharmaceutical industry is primarily focused on developing and manufacturing medications for various diseases and medical conditions. The biotechnology industry, on the other hand, focuses on the application of technology to biology and healthcare. Biologics testing includes tests to identify and quantify impurities, assess stability, and evaluate the immune response to the drug. The growth of the pharmaceutical and biotechnology industries has also led to advances in biologics testing technology, such as the development of new analytical tools and techniques. This has allowed for more accurate and efficient testing, reducing the time and cost of bringing new biologics to market. For instance, in June 2022, according to the European Federation of Pharmaceutical Industries and Associations, a Brussels-based trade association and lobbying organization, the European pharmaceutical production increased by 4.64% from € 286,697 million ($307,416 million) in 2020 to € 300,000 million ($321,681 million) in 2021. Further, in 2021, according to Torys LLP, a Canada-based corporate law firm, 84 initial public offerings for biotech companies in the US in 2020 raised a total of US$15 billion. Therefore, the rapidly growing pharmaceutical and biotechnology industries are driving the growth of the biologics testing market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=10276&type=smp

The biologics testing market covered in this report is segmented –

1) By Product: Reagents And Kits, Instruments, Other Products

2) By Test Type: Endotoxin Test, Sterility Test, Mycoplasma Tests, Bioburden Tests, Residual Host-Cell Proteins And DNA Detection Tests, Virus Safety Test, Other Test Types

3) By Application: Vaccine Development And Manufacturing, Monoclonal Antibodies Development And Manufacturing, Cellular And Gene Therapy Products Development And Manufacturing, Blood And Blood Products Development And Manufacturing, Other Applications

Product Innovations are a key trend gaining popularity in the biologics testing market. Companies operating in the biologics testing market are adopting new innovative products to sustain their position in the market. For instance, in December 2022, Charles River Laboratories International, Inc., a US-based non-clinical contract research organization, launched the Endosafe Nexus 200TM, a new addition to its broad endotoxin testing line. The Nexus 200 is a data integrity compliant, fully robotic instrument that is the next step in Charles River’s evolution. It uses Endosafe Limulus Amebocyte Lysate (LAL) cartridge technology and can process simple or complex serial dilutions for water, in-process, and final product testing. The system, which is run on Endosafe EndoScan-V version 6.1, enables data to be exported into a Laboratory Information Management System (LIMS) interface and offers enhanced traceability, security, and data management on an integrated touch screen.

The biologics testing market report table of contents includes:

1. Executive Summary

2. Biologics Testing Market Characteristics

3. Biologics Testing Market Trends And Strategies

4. Biologics Testing Market – Macro Economic Scenario

5. Global Biologics Testing Market Size and Growth

26. South America Biologics Testing Market

27. Brazil Biologics Testing Market

28. Middle East Biologics Testing Market

29. Africa Biologics Testing Market

30. Biologics Testing Market Competitive Landscape And Company Profiles

Top Major Players: